| Data suggest that over-expression of microRNA-133a in breast cancer cells results in down-regulation of EGFR expression; this leads to suppression of phosphorylation of proto-oncogene c-Akt (p-Akt) and inhibition of p-Akt nuclear translocation. | breast, |
| Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non-small cell lung cancer. | lung, |
| Oncogenic activation of EGFRvIII in glioblastoma is likely maintained by a continuous EGFR-EGFRvIII-HB-EGF feedback loop. | glioblastoma, |
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. | lung, |
| findings show that autochthonous EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase proinflammatory cytokines; these findings indicate EGFR functions as an oncogene through non-cell-autonomous mechanisms | lung, |
| Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. | lymphoma,sarcoma,lung, |
| Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. | lung, |
| Absence of EGFR, ERBB2 and ERBB4 mutation homologous to the oncogenic ERBB3 Val-104 mutation in colorectal cancers. | colorectal, |
| Oncogenic EGFR upregulated mir31 in lung carcinogenesis. | lung, |
| Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFalpha in glioblastoma. | glioblastoma, |
| Pharmacotherapy targeting the EGFR oncogene in NSCLC. | lung, |
| Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics. | lung, |
| Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma. | lung, |
| Addition of the EGFR inhibitor gefitinib restores the sensitivity of SMARCE1-knockdown cells to MET and ALK inhibitors in NSCLCs. Our findings link SMARCE1 to EGFR oncogenic signaling and suggest targeted treatment options for SMARCE1-deficient tumors. | lung, |
| The lack of response to EGFR inhibitors in EGFR mutated lung cancer may indicate that tumor differentiation affects tumor dependency on EGFR as a driver oncogene. | lung, |
| Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma. | breast, |
| Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations. | skin, |
| Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. | lung, |
| NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. | lung, |
| EGFR: The Paradigm of an Oncogene-Driven Lung Cancer. | lung, |